drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB08827 | DB11363 | 990 | 1,276 | [
"DDInter1085",
"DDInter39"
] | Lomitapide | Alectinib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Major | 2 | [
[
[
990,
25,
1276
]
],
[
[
990,
64,
305
],
[
305,
24,
1276
]
],
[
[
990,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
990,
63,
322
],
[
322,
... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alectinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparag... | Lomitapide may lead to a major life threatening interaction when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Lomitapide may lead to a major life threatening interaction when taken with Fingolimod and... |
DB08875 | DB11796 | 1,618 | 1,612 | [
"DDInter262",
"DDInter786"
] | Cabozantinib | Fostemsavir | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Major | 2 | [
[
[
1618,
25,
1612
]
],
[
[
1618,
63,
1051
],
[
1051,
23,
1612
]
],
[
[
1618,
24,
98
],
[
98,
23,
1612
]
],
[
[
1618,
24,
1476
],
[
1476,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Soma... |
DB00710 | DB01276 | 1,199 | 123 | [
"DDInter897",
"DDInter706"
] | Ibandronate | Exenatide | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1199,
24,
123
]
],
[
[
1199,
24,
848
],
[
848,
24,
123
]
],
[
[
1199,
63,
91
],
[
91,
24,
123
]
],
[
[
1199,
25,
629
],
[
629,
2... | [
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomy... |
DB01068 | DB11569 | 1,565 | 1,093 | [
"DDInter411",
"DDInter1003"
] | Clonazepam | Ixekizumab | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
1565,
24,
1093
]
],
[
[
1565,
63,
608
],
[
608,
24,
1093
]
],
[
[
1565,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
1565,
40,
1382
],
[
1382... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekin... |
DB00188 | DB12015 | 168 | 1,033 | [
"DDInter222",
"DDInter53"
] | Bortezomib | Alpelisib | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
168,
24,
1033
]
],
[
[
168,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
168,
25,
1510
],
[
1510,
24,
1033
]
],
[
[
168,
23,
1335
],
[
1335,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Bortezomib may lead to a major life threatening interaction when taken with Teriflunomide and Terif... |
DB01177 | DB14509 | 77 | 1,399 | [
"DDInter904",
"DDInter1081"
] | Idarubicin | Lithium carbonate | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
77,
24,
1399
]
],
[
[
77,
63,
589
],
[
589,
23,
1399
]
],
[
[
77,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
77,
63,
1010
],
[
1010,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Ab... |
DB01210 | DB09340 | 668 | 1,013 | [
"DDInter1050",
"DDInter1895"
] | Levobunolol (ophthalmic) | Tyropanoic acid | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
668,
24,
1013
]
],
[
[
668,
24,
777
],
[
777,
24,
1013
]
],
[
[
668,
40,
461
],
[
461,
24,
1013
]
],
[
[
668,
63,
1431
],
[
1431,
... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
],
... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide and Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
... |
DB00388 | DB00657 | 1,636 | 1,360 | [
"DDInter1453",
"DDInter1130"
] | Phenylephrine | Mecamylamine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. | Moderate | 1 | [
[
[
1636,
24,
1360
]
],
[
[
1636,
21,
28789
],
[
28789,
60,
1360
]
],
[
[
1636,
24,
1344
],
[
1344,
63,
1360
]
],
[
[
1636,
1,
874
],
[
87... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecamylamine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
... | Phenylephrine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mecamylamine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exace... |
DB00006 | DB04932 | 942 | 1,564 | [
"DDInter217",
"DDInter491"
] | Bivalirudin | Defibrotide | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Major | 2 | [
[
[
942,
25,
1564
]
],
[
[
942,
23,
297
],
[
297,
62,
1564
]
],
[
[
942,
24,
914
],
[
914,
24,
1564
]
],
[
[
942,
24,
41
],
[
41,
63... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may ca... |
DB00820 | DB09073 | 402 | 951 | [
"DDInter1736",
"DDInter1379"
] | Tadalafil | Palbociclib | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
402,
24,
951
]
],
[
[
402,
24,
1476
],
[
1476,
63,
951
]
],
[
[
402,
63,
600
],
[
600,
24,
951
]
],
[
[
402,
24,
1040
],
[
1040,
... | [
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flucon... |
DB00754 | DB05679 | 157 | 1,683 | [
"DDInter696",
"DDInter1907"
] | Ethotoin | Ustekinumab | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
157,
24,
1683
]
],
[
[
157,
24,
281
],
[
281,
24,
1683
]
],
[
[
157,
63,
305
],
[
305,
24,
1683
]
],
[
[
157,
62,
608
],
[
608,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamisole"
],
[
... | Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Levamisole and Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia... |
DB01157 | DB15091 | 304 | 676 | [
"DDInter1875",
"DDInter1901"
] | Trimetrexate | Upadacitinib | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
304,
25,
676
]
],
[
[
304,
24,
1430
],
[
1430,
24,
676
]
],
[
[
304,
62,
600
],
[
600,
24,
676
]
],
[
[
304,
63,
563
],
[
563,
2... | [
[
[
"Trimetrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Si... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Trimetrexate may cause a minor interaction that can limit clinical effects when taken with Fluconazole a... |
DB00468 | DB12332 | 1,424 | 1,619 | [
"DDInter1557",
"DDInter1626"
] | Quinine | Rucaparib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1424,
24,
1619
]
],
[
[
1424,
23,
307
],
[
307,
23,
1619
]
],
[
[
1424,
24,
87
],
[
87,
24,
1619
]
],
[
[
1424,
63,
1100
],
[
1100,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modaf... | Quinine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause ... |
DB00474 | DB00501 | 1,269 | 752 | [
"DDInter1173",
"DDInter380"
] | Methohexital | Cimetidine | An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Minor | 0 | [
[
[
1269,
23,
752
]
],
[
[
1269,
21,
28778
],
[
28778,
60,
752
]
],
[
[
1269,
40,
1023
],
[
1023,
23,
752
]
],
[
[
1269,
1,
288
],
[
288,
... | [
[
[
"Methohexital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Methohexital",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (... | Methohexital (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Cimetidine (Compound)
Methohexital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Methohexital (Comp... |
DB00631 | DB00773 | 372 | 896 | [
"DDInter405",
"DDInter702"
] | Clofarabine | Etoposide | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
372,
24,
896
]
],
[
[
372,
5,
11555
],
[
11555,
44,
896
]
],
[
[
372,
6,
17404
],
[
17404,
45,
896
]
],
[
[
372,
7,
6628
],
[
6628,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Clofarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disea... | Clofarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Etoposide (Compound)
Clofarabine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Etoposide (Compound)
Clofarabine (Compound) upregulates PMAIP1 (Gene) and PMAIP1 (Gene) is upregulated by Etoposide (Compo... |
DB00694 | DB09291 | 51 | 741 | [
"DDInter485",
"DDInter1615"
] | Daunorubicin | Rolapitant | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
51,
24,
741
]
],
[
[
51,
24,
479
],
[
479,
23,
741
]
],
[
[
51,
25,
924
],
[
924,
24,
741
]
],
[
[
51,
24,
1671
],
[
1671,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Daunorubicin may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone may caus... |
DB01236 | DB06788 | 679 | 1,616 | [
"DDInter1664",
"DDInter864"
] | Sevoflurane | Histrelin | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
679,
24,
1616
]
],
[
[
679,
62,
112
],
[
112,
23,
1616
]
],
[
[
679,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
679,
63,
77
],
[
77,
... | [
[
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Sevoflurane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sevoflurane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Rom... |
DB01177 | DB14444 | 77 | 151 | [
"DDInter904",
"DDInter924"
] | Idarubicin | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
77,
24,
151
]
],
[
[
77,
63,
66
],
[
66,
24,
151
]
],
[
[
77,
24,
1619
],
[
1619,
24,
151
]
],
[
[
77,
64,
550
],
[
550,
24,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could e... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Idarubicin may cause a moderate inter... |
DB00285 | DB00514 | 1,100 | 506 | [
"DDInter1927",
"DDInter527"
] | Venlafaxine | Dextromethorphan | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Major | 2 | [
[
[
1100,
25,
506
]
],
[
[
1100,
40,
534
],
[
534,
40,
506
]
],
[
[
1100,
6,
8374
],
[
8374,
45,
506
]
],
[
[
1100,
21,
28810
],
[
28810,
... | [
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
],
[
"Tramadol",
"{u} (Compound) resembles {v} (Comp... | Venlafaxine (Compound) resembles Tramadol (Compound) and Tramadol (Compound) resembles Dextromethorphan (Compound)
Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dextromethorphan (Compound)
Venlafaxine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect... |
DB00938 | DB08875 | 455 | 1,618 | [
"DDInter1635",
"DDInter262"
] | Salmeterol | Cabozantinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
455,
24,
1618
]
],
[
[
455,
25,
384
],
[
384,
63,
1618
]
],
[
[
455,
63,
307
],
[
307,
24,
1618
]
],
[
[
455,
24,
1032
],
[
1032,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalis... | Salmeterol may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause ... |
DB00352 | DB06589 | 482 | 1,250 | [
"DDInter1814",
"DDInter1400"
] | Tioguanine | Pazopanib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
482,
24,
1250
]
],
[
[
482,
21,
28868
],
[
28868,
60,
1250
]
],
[
[
482,
24,
1247
],
[
1247,
23,
1250
]
],
[
[
482,
24,
1151
],
[
1151... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is cau... | Tioguanine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Pazopanib (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken w... |
DB01144 | DB09472 | 1,326 | 1,383 | [
"DDInter540",
"DDInter1693"
] | Diclofenamide | Sodium sulfate | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1326,
24,
1383
]
],
[
[
1326,
1,
674
],
[
674,
24,
1383
]
],
[
[
1326,
24,
657
],
[
657,
63,
1383
]
],
[
[
1326,
64,
1479
],
[
1479,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
... | Diclofenamide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moder... |
DB08865 | DB09046 | 1,593 | 1,094 | [
"DDInter448",
"DDInter1201"
] | Crizotinib | Metreleptin | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
1593,
24,
1094
]
],
[
[
1593,
25,
230
],
[
230,
62,
1094
]
],
[
[
1593,
25,
1135
],
[
1135,
63,
1094
]
],
[
[
1593,
64,
866
],
[
866,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
],
[
"Relugolix"... | Crizotinib may lead to a major life threatening interaction when taken with Relugolix and Relugolix may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Crizotinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moderate interacti... |
DB00451 | DB00960 | 542 | 887 | [
"DDInter1064",
"DDInter1471"
] | Levothyroxine | Pindolol | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Minor | 0 | [
[
[
542,
23,
887
]
],
[
[
542,
23,
819
],
[
819,
40,
887
]
],
[
[
542,
62,
88
],
[
88,
40,
887
]
],
[
[
542,
23,
1121
],
[
1121,
1,
... | [
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pindolol"
]
],
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
... | Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Pindolol (Compound)
Le... |
DB00436 | DB00586 | 323 | 1,512 | [
"DDInter179",
"DDInter537"
] | Bendroflumethiazide | Diclofenac | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
323,
24,
1512
]
],
[
[
323,
21,
28680
],
[
28680,
60,
1512
]
],
[
[
323,
24,
885
],
[
885,
63,
1512
]
],
[
[
323,
40,
178
],
[
178,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect)... | Bendroflumethiazide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Diclofenac (Compound)
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00630 | DB13749 | 1,485 | 1,473 | [
"DDInter42",
"DDInter1116"
] | Alendronic acid | Magnesium gluconate | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
1485,
24,
1473
]
],
[
[
1485,
24,
544
],
[
544,
24,
1473
]
],
[
[
1485,
1,
1008
],
[
1008,
24,
1473
]
],
[
[
1485,
24,
544
],
[
544,
... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesiu... | Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Alendronic acid (Compound) resembles Risedronic acid (Compound) and Risedronic acid ... |
DB00631 | DB11967 | 372 | 710 | [
"DDInter405",
"DDInter210"
] | Clofarabine | Binimetinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
372,
24,
710
]
],
[
[
372,
24,
1593
],
[
1593,
24,
710
]
],
[
[
372,
24,
68
],
[
68,
63,
710
]
],
[
[
372,
63,
883
],
[
883,
24,... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and... |
DB00231 | DB00434 | 1,174 | 13 | [
"DDInter1761",
"DDInter459"
] | Temazepam | Cyproheptadine | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
1174,
24,
13
]
],
[
[
1174,
24,
104
],
[
104,
63,
13
]
],
[
[
1174,
1,
11305
],
[
11305,
1,
13
]
],
[
[
1174,
21,
29455
],
[
29455,
... | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Temazepam (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Cyproheptadine... |
DB00938 | DB06448 | 455 | 171 | [
"DDInter1635",
"DDInter1087"
] | Salmeterol | Lonafarnib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Major | 2 | [
[
[
455,
25,
171
]
],
[
[
455,
24,
222
],
[
222,
23,
171
]
],
[
[
455,
62,
1351
],
[
1351,
24,
171
]
],
[
[
455,
63,
888
],
[
888,
2... | [
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Flunisolide and Fluniso... |
DB00191 | DB09082 | 73 | 659 | [
"DDInter1447",
"DDInter1934"
] | Phentermine | Vilanterol | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
73,
24,
659
]
],
[
[
73,
24,
1296
],
[
1296,
63,
659
]
],
[
[
73,
36,
1161
],
[
1161,
24,
659
]
],
[
[
73,
24,
1450
],
[
1450,
2... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phentermine (Compound) resembles Selegiline (Compound) and Phentermine may lead to a major life thr... |
DB08864 | DB09104 | 786 | 286 | [
"DDInter1595",
"DDInter1118"
] | Rilpivirine | Magnesium hydroxide | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
786,
24,
286
]
],
[
[
786,
63,
820
],
[
820,
23,
286
]
],
[
[
786,
64,
752
],
[
752,
23,
286
]
],
[
[
786,
63,
688
],
[
688,
24,... | [
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Rilpivirine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine... |
DB00572 | DB09272 | 85 | 412 | [
"DDInter136",
"DDInter632"
] | Atropine | Eluxadoline | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
85,
24,
412
]
],
[
[
85,
63,
1594
],
[
1594,
24,
412
]
],
[
[
85,
24,
543
],
[
543,
24,
412
]
],
[
[
85,
24,
1536
],
[
1536,
63,... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamid... |
DB00008 | DB00108 | 491 | 1,066 | [
"DDInter1407",
"DDInter1268"
] | Peginterferon alfa-2a | Natalizumab | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Major | 2 | [
[
[
491,
25,
1066
]
],
[
[
491,
24,
1430
],
[
1430,
63,
1066
]
],
[
[
491,
24,
375
],
[
375,
64,
1066
]
],
[
[
491,
25,
1011
],
[
1011,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Natalizumab
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken... |
DB00563 | DB05528 | 663 | 1,070 | [
"DDInter1174",
"DDInter1228"
] | Methotrexate | Mipomersen | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
663,
25,
1070
]
],
[
[
663,
24,
292
],
[
292,
64,
1070
]
],
[
[
663,
25,
1512
],
[
1512,
25,
1070
]
],
[
[
663,
24,
14
],
[
14,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regor... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Methotrexate may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major... |
DB00530 | DB00585 | 1,195 | 1,127 | [
"DDInter667",
"DDInter1309"
] | Erlotinib | Nizatidine | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Moderate | 1 | [
[
[
1195,
24,
1127
]
],
[
[
1195,
24,
1194
],
[
1194,
40,
1127
]
],
[
[
1195,
6,
4973
],
[
4973,
45,
1127
]
],
[
[
1195,
7,
2216
],
[
2216... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nizatidine"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine (Compound) resembles Nizatidine (Compound)
Erlotinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nizatidine (Compound)
Erlotinib (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregu... |
DB00019 | DB12893 | 1,257 | 586 | [
"DDInter1405",
"DDInter1629"
] | Pegfilgrastim | Sacituzumab govitecan | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Moderate | 1 | [
[
[
1257,
24,
586
]
],
[
[
1257,
24,
869
],
[
869,
24,
586
]
],
[
[
1257,
25,
1064
],
[
1064,
25,
586
]
],
[
[
1257,
24,
1619
],
[
1619,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladri... |
DB00855 | DB00880 | 213 | 359 | [
"DDInter72",
"DDInter360"
] | Aminolevulinic acid | Chlorothiazide | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Major | 2 | [
[
[
213,
25,
359
]
],
[
[
213,
64,
1577
],
[
1577,
1,
359
]
],
[
[
213,
25,
504
],
[
504,
1,
359
]
],
[
[
213,
21,
28784
],
[
28784,
... | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroflumethiazide"
],
[
... | Aminolevulinic acid may lead to a major life threatening interaction when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Aminolevulinic acid may lead to a major life threatening interaction when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resemb... |
DB00215 | DB00581 | 1,230 | 355 | [
"DDInter388",
"DDInter1018"
] | Citalopram | Lactulose | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
1230,
24,
355
]
],
[
[
1230,
21,
28750
],
[
28750,
60,
355
]
],
[
[
1230,
24,
286
],
[
286,
62,
355
]
],
[
[
1230,
25,
79
],
[
79,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Citalopram",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal discomfort"
],
[
"Abdominal discomfort",
"{u} ... | Citalopram (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Lactulose (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit cli... |
DB01267 | DB14568 | 519 | 982 | [
"DDInter1381",
"DDInter1000"
] | Paliperidone | Ivosidenib | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
519,
25,
982
]
],
[
[
519,
62,
112
],
[
112,
23,
982
]
],
[
[
519,
63,
543
],
[
543,
24,
982
]
],
[
[
519,
24,
28
],
[
28,
24,
... | [
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and ... |
DB00395 | DB11130 | 210 | 407 | [
"DDInter301",
"DDInter1344"
] | Carisoprodol | Opium | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
210,
24,
407
]
],
[
[
210,
24,
662
],
[
662,
24,
407
]
],
[
[
210,
63,
1214
],
[
1214,
24,
407
]
],
[
[
210,
64,
475
],
[
475,
2... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Mi... |
DB00850 | DB05812 | 1,630 | 1,374 | [
"DDInter1432",
"DDInter8"
] | Perphenazine | Abiraterone | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1630,
24,
1374
]
],
[
[
1630,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1630,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
1630,
23,
112
],
[
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compou... | Perphenazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Perphenazine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Perphenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00290 | DB00970 | 329 | 0 | [
"DDInter219",
"DDInter466"
] | Bleomycin | Dactinomycin | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Moderate | 1 | [
[
[
329,
24,
0
]
],
[
[
329,
5,
11600
],
[
11600,
44,
0
]
],
[
[
329,
21,
28701
],
[
28701,
60,
0
]
],
[
[
329,
23,
246
],
[
246,
62... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
]
],
[
[
"Bleomycin",
"{u} (Compound) treats {v} (Disease)",
"germ cell cancer"
],
[
"germ cell cancer",
"{u} (Disease) i... | Bleomycin (Compound) treats germ cell cancer (Disease) and germ cell cancer (Disease) is treated by Dactinomycin (Compound)
Bleomycin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Dactinomycin (Compound)
Bleomycin may cause a minor interaction that can limit clinical effects when ... |
DB00294 | DB11569 | 1,336 | 1,093 | [
"DDInter701",
"DDInter1003"
] | Etonogestrel | Ixekizumab | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
1336,
24,
1093
]
],
[
[
1336,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
1336,
1,
873
],
[
873,
24,
1093
]
],
[
[
1336,
63,
58
],
[
58,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Etonogestrel (Compound) resembles Norgestimate (Compound) and Norgestimate may cause a moderate interaction ... |
DB00398 | DB04835 | 79 | 1,655 | [
"DDInter1702",
"DDInter1125"
] | Sorafenib | Maraviroc | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
79,
24,
1655
]
],
[
[
79,
6,
8374
],
[
8374,
45,
1655
]
],
[
[
79,
7,
7247
],
[
7247,
57,
1655
]
],
[
[
79,
21,
28792
],
[
28792,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound)
Sorafenib (Compound) upregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Maraviroc (Compound)
Sorafenib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by... |
DB01114 | DB09061 | 272 | 1,627 | [
"DDInter362",
"DDInter284"
] | Chlorpheniramine | Cannabidiol | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
272,
24,
1627
]
],
[
[
272,
24,
760
],
[
760,
62,
1627
]
],
[
[
272,
74,
1594
],
[
1594,
24,
1627
]
],
[
[
272,
24,
39
],
[
39,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Chlorpheniramine (Compound) resembles Doxylamine (Compound) and Chlorpheniramine may cause a moderate inter... |
DB00773 | DB01042 | 896 | 1,307 | [
"DDInter702",
"DDInter1144"
] | Etoposide | Melphalan | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
896,
24,
1307
]
],
[
[
896,
24,
1191
],
[
1191,
1,
1307
]
],
[
[
896,
5,
11618
],
[
11618,
44,
1307
]
],
[
[
896,
7,
3151
],
[
3151,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
],
[
"... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Melphalan (Compound)
Etoposide (Compound) treats peripheral nervous system neoplasm (Disease) and peripheral nervous system neoplasm (Disease) is treated by Melphalan (Compound)
Etoposide... |
DB00740 | DB08880 | 424 | 1,510 | [
"DDInter1596",
"DDInter1771"
] | Riluzole | Teriflunomide | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
424,
25,
1510
]
],
[
[
424,
62,
1031
],
[
1031,
24,
1510
]
],
[
[
424,
24,
985
],
[
985,
64,
1510
]
],
[
[
424,
24,
850
],
[
850,
... | [
[
[
"Riluzole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Riluzole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophyllin... | Riluzole may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Riluzole may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osim... |
DB09082 | DB12141 | 659 | 971 | [
"DDInter1934",
"DDInter817"
] | Vilanterol | Gilteritinib | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
659,
24,
971
]
],
[
[
659,
63,
485
],
[
485,
24,
971
]
],
[
[
659,
24,
730
],
[
730,
63,
971
]
],
[
[
659,
24,
1297
],
[
1297,
2... | [
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[... | Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine ... |
DB00252 | DB01176 | 362 | 537 | [
"DDInter1460",
"DDInter453"
] | Phenytoin | Cyclizine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
362,
24,
537
]
],
[
[
362,
24,
1242
],
[
1242,
24,
537
]
],
[
[
362,
24,
104
],
[
104,
1,
537
]
],
[
[
362,
1,
11288
],
[
11288,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdil... |
DB00649 | DB06317 | 231 | 1,626 | [
"DDInter1710",
"DDInter630"
] | Stavudine | Elotuzumab | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
231,
24,
1626
]
],
[
[
231,
24,
973
],
[
973,
24,
1626
]
],
[
[
231,
63,
597
],
[
597,
24,
1626
]
],
[
[
231,
24,
310
],
[
310,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chl... |
DB00446 | DB14975 | 597 | 988 | [
"DDInter351",
"DDInter1949"
] | Chloramphenicol | Voxelotor | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
597,
24,
988
]
],
[
[
597,
23,
466
],
[
466,
23,
988
]
],
[
[
597,
24,
629
],
[
629,
24,
988
]
],
[
[
597,
63,
254
],
[
254,
24,... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],... | Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus an... |
DB00515 | DB15091 | 589 | 676 | [
"DDInter387",
"DDInter1901"
] | Cisplatin | Upadacitinib | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
589,
25,
676
]
],
[
[
589,
63,
1461
],
[
1461,
23,
676
]
],
[
[
589,
24,
1430
],
[
1430,
24,
676
]
],
[
[
589,
63,
597
],
[
597,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleuc... |
DB00640 | DB01259 | 1,585 | 392 | [
"DDInter31",
"DDInter1024"
] | Adenosine | Lapatinib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1585,
24,
392
]
],
[
[
1585,
18,
10780
],
[
10780,
46,
392
]
],
[
[
1585,
21,
28695
],
[
28695,
60,
392
]
],
[
[
1585,
24,
918
],
[
91... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Adenosine",
"{u} (Compound) downregulates {v} (Gene)",
"CCNB2"
],
[
"CCNB2",
"{u} (Gene) is upregulated by {v} (Co... | Adenosine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by Lapatinib (Compound)
Adenosine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Lapatinib (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide a... |
DB11730 | DB14975 | 351 | 988 | [
"DDInter1588",
"DDInter1949"
] | Ribociclib | Voxelotor | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
351,
24,
988
]
],
[
[
351,
62,
222
],
[
222,
23,
988
]
],
[
[
351,
23,
466
],
[
466,
23,
988
]
],
[
[
351,
63,
251
],
[
251,
24,... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Ribociclib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutam... |
DB01611 | DB06288 | 1,487 | 607 | [
"DDInter893",
"DDInter77"
] | Hydroxychloroquine | Amisulpride | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
1487,
25,
607
]
],
[
[
1487,
21,
29232
],
[
29232,
60,
607
]
],
[
[
1487,
63,
112
],
[
112,
23,
607
]
],
[
[
1487,
63,
1559
],
[
1559,... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Hydroxychloroquine",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is ca... | Hydroxychloroquine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects wh... |
DB00734 | DB01233 | 1,664 | 1,311 | [
"DDInter1605",
"DDInter1197"
] | Risperidone | Metoclopramide | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Major | 2 | [
[
[
1664,
25,
1311
]
],
[
[
1664,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
1664,
64,
1425
],
[
1425,
40,
1311
]
],
[
[
1664,
6,
5289
],
[
528... | [
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunit... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Risperidone may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Metoclopramide (Compound)
Risperido... |
DB00863 | DB00981 | 1,194 | 1,528 | [
"DDInter1568",
"DDInter1462"
] | Ranitidine | Physostigmine | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
1194,
24,
1528
]
],
[
[
1194,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
1194,
62,
190
],
[
190,
24,
1528
]
],
[
[
1194,
64,
543
],
[
543... | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Ranitidine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is cau... | Ranitidine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Succinylcholine and Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00575 | DB01075 | 1,020 | 1,376 | [
"DDInter412",
"DDInter569"
] | Clonidine | Diphenhydramine | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
1020,
24,
1376
]
],
[
[
1020,
24,
649
],
[
649,
63,
1376
]
],
[
[
1020,
63,
128
],
[
128,
24,
1376
]
],
[
[
1020,
24,
832
],
[
832,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine... |
DB00816 | DB09038 | 1,674 | 1,450 | [
"DDInter1346",
"DDInter636"
] | Orciprenaline | Empagliflozin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1674,
24,
1450
]
],
[
[
1674,
64,
461
],
[
461,
24,
1450
]
],
[
[
1674,
63,
485
],
[
485,
24,
1450
]
],
[
[
1674,
24,
659
],
[
659,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timo... | Orciprenaline may lead to a major life threatening interaction when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may c... |
DB06616 | DB06674 | 594 | 908 | [
"DDInter224",
"DDInter837"
] | Bosutinib | Golimumab | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
594,
25,
908
]
],
[
[
594,
63,
336
],
[
336,
24,
908
]
],
[
[
594,
64,
697
],
[
697,
24,
908
]
],
[
[
594,
24,
1586
],
[
1586,
6... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Bosutinib may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cau... |
DB00196 | DB00204 | 600 | 228 | [
"DDInter743",
"DDInter580"
] | Fluconazole | Dofetilide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Major | 2 | [
[
[
600,
25,
228
]
],
[
[
600,
25,
540
],
[
540,
1,
228
]
],
[
[
600,
6,
8374
],
[
8374,
45,
228
]
],
[
[
600,
21,
28810
],
[
28810,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{... | Fluconazole may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Dofetilide (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dofetilide (Compound)
Fluconazole (Compound) causes Gastrointestinal pain (Side Effect) and Gastroi... |
DB00719 | DB11601 | 1,219 | 1,270 | [
"DDInter149",
"DDInter1889"
] | Azatadine | Tuberculin purified protein derivative | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1219,
24,
1270
]
],
[
[
1219,
63,
13
],
[
13,
24,
1270
]
],
[
[
1219,
24,
1053
],
[
1053,
24,
1270
]
],
[
[
1219,
40,
830
],
[
830,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Azatadine may cause a moderate interaction that could exacerbate diseases whe... |
DB00014 | DB00862 | 521 | 1,005 | [
"DDInter839",
"DDInter1918"
] | Goserelin | Vardenafil | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Moderate | 1 | [
[
[
521,
24,
1005
]
],
[
[
521,
21,
28988
],
[
28988,
60,
1005
]
],
[
[
521,
23,
112
],
[
112,
63,
1005
]
],
[
[
521,
24,
1494
],
[
1494,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vardenafil"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Amnesia"
],
[
"Amnesia",
"{u} (Side Effect) is caused by ... | Goserelin (Compound) causes Amnesia (Side Effect) and Amnesia (Side Effect) is caused by Vardenafil (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Vardenafi... |
DB00041 | DB00395 | 1,648 | 210 | [
"DDInter38",
"DDInter301"
] | Aldesleukin | Carisoprodol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications . This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with ... | Moderate | 1 | [
[
[
1648,
24,
210
]
],
[
[
1648,
24,
1050
],
[
1050,
40,
210
]
],
[
[
1648,
24,
1264
],
[
1264,
63,
210
]
],
[
[
1648,
24,
1242
],
[
1242,... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carisoprodol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meprobamate"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Meprobamate and Meprobamate (Compound) resembles Carisoprodol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could... |
DB00471 | DB01110 | 201 | 86 | [
"DDInter1242",
"DDInter1209"
] | Montelukast | Miconazole | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
201,
24,
86
]
],
[
[
201,
6,
8717
],
[
8717,
45,
86
]
],
[
[
201,
21,
29122
],
[
29122,
60,
86
]
],
[
[
201,
24,
690
],
[
690,
2... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)... | Montelukast (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Miconazole (Compound)
Montelukast (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken... |
DB00344 | DB08865 | 1,302 | 1,593 | [
"DDInter1543",
"DDInter448"
] | Protriptyline | Crizotinib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1302,
25,
1593
]
],
[
[
1302,
6,
4973
],
[
4973,
45,
1593
]
],
[
[
1302,
7,
5301
],
[
5301,
46,
1593
]
],
[
[
1302,
18,
4374
],
[
4374... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Cri... | Protriptyline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Protriptyline (Compound) upregulates CDK19 (Gene) and CDK19 (Gene) is upregulated by Crizotinib (Compound)
Protriptyline (Compound) downregulates SDHB (Gene) and SDHB (Gene) is downregulated by Crizotinib (Compound)
Protripty... |
DB01030 | DB11703 | 869 | 405 | [
"DDInter1835",
"DDInter9"
] | Topotecan | Acalabrutinib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
869,
24,
405
]
],
[
[
869,
63,
139
],
[
139,
24,
405
]
],
[
[
869,
24,
248
],
[
248,
24,
405
]
],
[
[
869,
24,
151
],
[
151,
63,... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and V... |
DB00963 | DB09134 | 1,263 | 1,552 | [
"DDInter241",
"DDInter966"
] | Bromfenac | Ioversol | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
1263,
25,
1552
]
],
[
[
1263,
24,
848
],
[
848,
25,
1552
]
],
[
[
1263,
63,
1274
],
[
1274,
25,
1552
]
],
[
[
1263,
1,
24
],
[
24,
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Ioversol
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to ... |
DB00818 | DB00916 | 898 | 112 | [
"DDInter1538",
"DDInter1202"
] | Propofol | Metronidazole | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
898,
23,
112
]
],
[
[
898,
6,
3486
],
[
3486,
45,
112
]
],
[
[
898,
21,
28640
],
[
28640,
60,
112
]
],
[
[
898,
63,
618
],
[
618,
... | [
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Propofol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Propofol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Propofol (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Metronidazole (Compound)
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abar... |
DB00346 | DB09472 | 472 | 1,383 | [
"DDInter44",
"DDInter1693"
] | Alfuzosin | Sodium sulfate | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
472,
24,
1383
]
],
[
[
472,
25,
609
],
[
609,
24,
1383
]
],
[
[
472,
63,
521
],
[
521,
24,
1383
]
],
[
[
472,
24,
1342
],
[
1342,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clar... | Alfuzosin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin ma... |
DB00197 | DB04868 | 1,324 | 478 | [
"DDInter1881",
"DDInter1293"
] | Troglitazone | Nilotinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1324,
24,
478
]
],
[
[
1324,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1324,
23,
809
],
[
809,
62,
478
]
],
[
[
1324,
24,
1135
],
[
1135,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Ralteg... |
DB00472 | DB00682 | 758 | 126 | [
"DDInter758",
"DDInter1951"
] | Fluoxetine | Warfarin | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
758,
24,
126
]
],
[
[
758,
40,
847
],
[
847,
40,
126
]
],
[
[
758,
24,
1376
],
[
1376,
40,
126
]
],
[
[
758,
6,
7950
],
[
7950,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Fluoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resemble... | Fluoxetine (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Warfarin (Compound)
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound)
Fluoxetine (Compound) binds CYP1A2 (Gene... |
DB00436 | DB01017 | 323 | 1,669 | [
"DDInter179",
"DDInter1224"
] | Bendroflumethiazide | Minocycline | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Minor | 0 | [
[
[
323,
23,
1669
]
],
[
[
323,
23,
1572
],
[
1572,
1,
1669
]
],
[
[
323,
62,
964
],
[
964,
1,
1669
]
],
[
[
323,
40,
504
],
[
504,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycli... | Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembl... |
DB00736 | DB05541 | 660 | 801 | [
"DDInter676",
"DDInter239"
] | Esomeprazole | Brivaracetam | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Minor | 0 | [
[
[
660,
23,
801
]
],
[
[
660,
24,
477
],
[
477,
23,
801
]
],
[
[
660,
1,
1215
],
[
1215,
23,
801
]
],
[
[
660,
62,
168
],
[
168,
23... | [
[
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
... | Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Esomeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that ... |
DB00286 | DB00302 | 380 | 335 | [
"DDInter439",
"DDInter1844"
] | Conjugated estrogens | Tranexamic acid | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. It was first patented in 1957 and received its initial US approval in 1986. | Major | 2 | [
[
[
380,
25,
335
]
],
[
[
380,
21,
28762
],
[
28762,
60,
335
]
],
[
[
380,
40,
1438
],
[
1438,
64,
335
]
],
[
[
380,
1,
35
],
[
35,
... | [
[
[
"Conjugated estrogens",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tranexamic acid"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect)... | Conjugated estrogens (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tranexamic acid (Compound)
Conjugated estrogens (Compound) resembles Estradiol (Compound) and Estradiol may lead to a major life threatening interaction when taken with Tranexamic acid
Conjugated estrogens (Compound) r... |
DB01097 | DB11989 | 1,377 | 1,434 | [
"DDInter1033",
"DDInter183"
] | Leflunomide | Benznidazole | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
1377,
24,
1434
]
],
[
[
1377,
25,
788
],
[
788,
24,
1434
]
],
[
[
1377,
24,
148
],
[
148,
63,
1434
]
],
[
[
1377,
25,
1060
],
[
1060,
... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitavastatin"
],
[
"Pita... | Leflunomide may lead to a major life threatening interaction when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole ... |
DB09135 | DB14509 | 1,211 | 1,399 | [
"DDInter967",
"DDInter1081"
] | Ioxilan | Lithium carbonate | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Major | 2 | [
[
[
1211,
25,
1399
]
],
[
[
1211,
64,
589
],
[
589,
23,
1399
]
],
[
[
1211,
63,
1574
],
[
1574,
23,
1399
]
],
[
[
1211,
64,
387
],
[
387,
... | [
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} ma... | Ioxilan may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Ioxilan may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a minor interac... |
DB01281 | DB09322 | 881 | 1,114 | [
"DDInter5",
"DDInter1966"
] | Abatacept | Zinc sulfate | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
881,
23,
1114
]
],
[
[
881,
63,
66
],
[
66,
23,
1114
]
],
[
[
881,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
881,
24,
259
],
[
259,
... | [
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Abatacept may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a ... |
DB06603 | DB11853 | 39 | 230 | [
"DDInter1387",
"DDInter1577"
] | Panobinostat | Relugolix | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
39,
25,
230
]
],
[
[
39,
25,
129
],
[
129,
23,
230
]
],
[
[
39,
24,
1094
],
[
1094,
23,
230
]
],
[
[
39,
62,
112
],
[
112,
23,
... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
... | Panobinostat may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may... |
DB00011 | DB00495 | 1,451 | 139 | [
"DDInter944",
"DDInter1961"
] | Interferon alfa-n1 | Zidovudine | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Major | 2 | [
[
[
1451,
25,
139
]
],
[
[
1451,
25,
1477
],
[
1477,
40,
139
]
],
[
[
1451,
24,
231
],
[
231,
40,
139
]
],
[
[
1451,
24,
309
],
[
309,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
],
[
"Telbivud... | Interferon alfa-n1 may lead to a major life threatening interaction when taken with Telbivudine and Telbivudine (Compound) resembles Zidovudine (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine (Compound) resembles Zidovudine (Compound)... |
DB00398 | DB06176 | 79 | 1,342 | [
"DDInter1702",
"DDInter1616"
] | Sorafenib | Romidepsin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
79,
24,
1342
]
],
[
[
79,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
79,
24,
956
],
[
956,
24,
1342
]
],
[
[
79,
24,
1616
],
[
1616,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Sorafenib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and... |
DB00468 | DB00564 | 1,424 | 1,236 | [
"DDInter1557",
"DDInter293"
] | Quinine | Carbamazepine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
1424,
24,
1236
]
],
[
[
1424,
23,
307
],
[
307,
1,
1236
]
],
[
[
1424,
63,
508
],
[
508,
1,
1236
]
],
[
[
1424,
24,
820
],
[
820,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"M... | Quinine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Carbamazepine (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Carbamazepine (Compound)
Quinin... |
DB00945 | DB09075 | 1,479 | 498 | [
"DDInter20",
"DDInter621"
] | Acetylsalicylic acid | Edoxaban | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1479,
25,
498
]
],
[
[
1479,
23,
944
],
[
944,
62,
498
]
],
[
[
1479,
24,
41
],
[
41,
24,
498
]
],
[
[
1479,
63,
109
],
[
109,
2... | [
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
... | Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Levomilna... |
DB00590 | DB09054 | 1,433 | 384 | [
"DDInter592",
"DDInter905"
] | Doxazosin | Idelalisib | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1433,
24,
384
]
],
[
[
1433,
40,
479
],
[
479,
23,
384
]
],
[
[
1433,
24,
891
],
[
891,
24,
384
]
],
[
[
1433,
63,
1648
],
[
1648,
... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor inter... | Doxazosin (Compound) resembles Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could e... |
DB08865 | DB11689 | 1,593 | 321 | [
"DDInter448",
"DDInter1659"
] | Crizotinib | Selumetinib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Major | 2 | [
[
[
1593,
25,
321
]
],
[
[
1593,
25,
982
],
[
982,
63,
321
]
],
[
[
1593,
64,
392
],
[
392,
24,
321
]
],
[
[
1593,
25,
498
],
[
498,
... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} ... | Crizotinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Crizotinib may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate inter... |
DB00047 | DB00373 | 176 | 461 | [
"DDInter932",
"DDInter1809"
] | Insulin glargine | Timolol | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Moderate | 1 | [
[
[
176,
24,
461
]
],
[
[
176,
24,
729
],
[
729,
40,
461
]
],
[
[
176,
24,
1479
],
[
1479,
62,
461
]
],
[
[
176,
24,
1152
],
[
1152,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a mi... |
DB00519 | DB11827 | 1,638 | 433 | [
"DDInter1843",
"DDInter669"
] | Trandolapril | Ertugliflozin | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1638,
24,
433
]
],
[
[
1638,
24,
959
],
[
959,
24,
433
]
],
[
[
1638,
63,
251
],
[
251,
24,
433
]
],
[
[
1638,
1,
954
],
[
954,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone an... |
DB00290 | DB11003 | 329 | 748 | [
"DDInter219",
"DDInter100"
] | Bleomycin | Anthrax vaccine | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
329,
24,
748
]
],
[
[
329,
24,
322
],
[
322,
24,
748
]
],
[
[
329,
25,
676
],
[
676,
63,
748
]
],
[
[
329,
64,
1057
],
[
1057,
2... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bleomycin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may... |
DB00564 | DB11130 | 1,236 | 407 | [
"DDInter293",
"DDInter1344"
] | Carbamazepine | Opium | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1236,
24,
407
]
],
[
[
1236,
24,
662
],
[
662,
24,
407
]
],
[
[
1236,
25,
976
],
[
976,
24,
407
]
],
[
[
1236,
63,
1233
],
[
1233,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Carbamazepine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib m... |
DB11793 | DB14444 | 738 | 151 | [
"DDInter1297",
"DDInter924"
] | Niraparib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
738,
24,
151
]
],
[
[
738,
63,
66
],
[
66,
24,
151
]
],
[
[
738,
24,
1619
],
[
1619,
24,
151
]
],
[
[
738,
64,
375
],
[
375,
24,... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exa... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Niraparib may cause a moderate interac... |
DB00980 | DB01246 | 969 | 820 | [
"DDInter1564",
"DDInter45"
] | Ramelteon | Alimemazine | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
969,
24,
820
]
],
[
[
969,
63,
104
],
[
104,
40,
820
]
],
[
[
969,
24,
401
],
[
401,
24,
820
]
],
[
[
969,
24,
649
],
[
649,
1,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB00701 | DB05812 | 1,091 | 1,374 | [
"DDInter90",
"DDInter8"
] | Amprenavir | Abiraterone | Amprenavir is a protease inhibitor used to treat HIV infection. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Minor | 0 | [
[
[
1091,
23,
1374
]
],
[
[
1091,
6,
10417
],
[
10417,
45,
1374
]
],
[
[
1091,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
1091,
23,
466
],
[
... | [
[
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
... | Amprenavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Abiraterone (Compound)
Amprenavir (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Amprenavir may cause a minor interaction that can limit clinical effects when take... |
DB00468 | DB00705 | 1,424 | 441 | [
"DDInter1557",
"DDInter496"
] | Quinine | Delavirdine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Moderate | 1 | [
[
[
1424,
24,
441
]
],
[
[
1424,
6,
21998
],
[
21998,
45,
441
]
],
[
[
1424,
21,
28709
],
[
28709,
60,
441
]
],
[
[
1424,
24,
1374
],
[
13... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v}... | Quinine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Delavirdine (Compound)
Quinine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when t... |
DB00983 | DB01100 | 480 | 1,568 | [
"DDInter776",
"DDInter1470"
] | Formoterol | Pimozide | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
480,
24,
1568
]
],
[
[
480,
63,
78
],
[
78,
40,
1568
]
],
[
[
480,
63,
1557
],
[
1557,
25,
1568
]
],
[
[
480,
6,
10215
],
[
10215,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interact... |
DB00563 | DB00744 | 663 | 1,288 | [
"DDInter1174",
"DDInter1962"
] | Methotrexate | Zileuton | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Moderate | 1 | [
[
[
663,
24,
1288
]
],
[
[
663,
21,
29232
],
[
29232,
60,
1288
]
],
[
[
663,
25,
629
],
[
629,
63,
1288
]
],
[
[
663,
63,
482
],
[
482,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is ca... | Methotrexate (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Zileuton (Compound)
Methotrexate may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Methotrexate ... |
DB00304 | DB08820 | 1,657 | 1,478 | [
"DDInter508",
"DDInter997"
] | Desogestrel | Ivacaftor | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1657,
24,
1478
]
],
[
[
1657,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
1657,
1,
1336
],
[
1336,
24,
1478
]
],
[
[
1657,
25,
1040
],
[
1... | [
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Desogestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is cause... | Desogestrel (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Desogestrel (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Desogestrel may lead to a major life threa... |
DB14723 | DB14975 | 159 | 988 | [
"DDInter1026",
"DDInter1949"
] | Larotrectinib | Voxelotor | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
159,
24,
988
]
],
[
[
159,
62,
222
],
[
222,
23,
988
]
],
[
[
159,
63,
251
],
[
251,
24,
988
]
],
[
[
159,
24,
676
],
[
676,
63,... | [
[
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and ... |
DB08895 | DB09036 | 976 | 812 | [
"DDInter1825",
"DDInter1668"
] | Tofacitinib | Siltuximab | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Major | 2 | [
[
[
976,
25,
812
]
],
[
[
976,
23,
1193
],
[
1193,
62,
812
]
],
[
[
976,
62,
1461
],
[
1461,
23,
812
]
],
[
[
976,
25,
287
],
[
287,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc g... | Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vit... |
DB00008 | DB00242 | 491 | 1,064 | [
"DDInter1407",
"DDInter392"
] | Peginterferon alfa-2a | Cladribine | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
491,
25,
1064
]
],
[
[
491,
24,
372
],
[
372,
64,
1064
]
],
[
[
491,
24,
869
],
[
869,
63,
1064
]
],
[
[
491,
24,
1253
],
[
1253,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Topotecan an... |
DB00381 | DB08907 | 376 | 1,344 | [
"DDInter79",
"DDInter280"
] | Amlodipine | Canagliflozin | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
376,
24,
1344
]
],
[
[
376,
24,
549
],
[
549,
1,
1344
]
],
[
[
376,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
376,
21,
28873
],
[
28873,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Amlodipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Amlodipine (Compound) causes Pancreatitis (Side Effect) ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.